Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by IMV Inc.
< Previous
1
2
Next >
IMV’s Lead Compound to Be Showcased in Two Presentations at the 2022 ASCO Annual Meeting
April 28, 2022
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV Inc. Names Michael P. Bailey Chairman of The Board
April 22, 2022
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV Inc. Presents Clinical Benefit of MVP-S in Combination with Pembrolizumab in Bladder Cancer at the AACR Annual Meeting
April 08, 2022
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV to Present at IMMUNOLOGY™ 2022, the AAI Annual Meeting
April 06, 2022
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV Inc. to Present at Two Upcoming Investor Conferences
April 04, 2022
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV Inc. Announces Fourth Quarter and Full Year 2021 Financial and Operational Results
March 17, 2022
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV to Host a Webcast to Highlight its Immune-Educating DPX® Platform
February 17, 2022
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL
January 12, 2022
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV Inc. to Present at Two Upcoming Investor Events
January 05, 2022
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV Appoints Andrew Hall as Chief Executive Officer
December 22, 2021
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts
December 21, 2021
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt Facility
December 20, 2021
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
Role of B Cells Induced by IMV’s Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress
December 02, 2021
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer
November 30, 2021
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV Inc. to Present at the Piper Sandler Virtual Healthcare Conference
November 23, 2021
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV Inc. Announces Chief Financial Officer to Retire
November 22, 2021
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV Inc. Announces Third Quarter 2021 Financial and Operational Update
November 10, 2021
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
Translational Data From the DeCidE1 Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting
November 09, 2021
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV Inc. to Announce Third Quarter 2021 Results and Host a Conference Call and Webcast on November 11, 2021
November 04, 2021
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
October 07, 2021
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
Potential Response Predictors to IMV’s Lead Compound in the DeCidE Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting
October 01, 2021
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV’s DPX Delivery Technology to be Showcased in Two e-Posters at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
September 30, 2021
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV Inc. to Present at Three Investor Conferences in September
September 01, 2021
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV Inc. Announces Second Quarter 2021 Financial and Operational Results
August 11, 2021
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV Announces Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer
August 10, 2021
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV Announces CEO Transition
August 04, 2021
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV Inc. to Announce Second Quarter 2021 Results and Host a Conference Call and Webcast on August 11, 2021
August 02, 2021
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV to Participate in the BTIG Virtual Biotechnology Conference
July 29, 2021
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV Inc. Closes Previously Announced Public Offering
July 20, 2021
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
IMV Inc. Announces Pricing of Public Offering
July 15, 2021
From
IMV Inc.
Via
Business Wire
Tickers
IMV
TSX:IMV
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.